Popular Articles
Cellulite Treatment

Molecular Typesetting -- Proofreading Without A Proofreader
Researchers at the Universities of Leeds and Bristol (UK) have developed a model of how errors are corrected whilst proteins are being built.
generic viagra online
The Challenges Of Avian Influenza Virus: Mechanism, Epidemiology And Control
The latest special issue of Science in China Series C: Life Sciences focuses on the recent progress in the H5N1-related research field.
News of the day
FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
Boston Scientific Corporation (NYSE: BSX) announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Mental Health

Merck & Co., Inc. Statement On Medicare Part D Assistance

Merck & Co., Inc. said it supports a proposal to provide additional assistance to Medicare Part D beneficiaries who have reached the coverage gap (donut hole) in their prescription benefit. Merck has a history of working to increase access to affordable health care and prescription drug coverage. In 2006, Merck supported the creation of the Medicare Part D program and continues to support its design and mission. Since its introduction, the Medicare Part D program has shown that beneficiaries" access to medicines has greatly improved and they are saving money. However, the dynamics of the Medicare Part D coverage gap have created some instability in the benefit for the consumer. Providing additional assistance in the coverage gap supports the success of the Medicare Part D program and mitigates cost hurdles for Medicare patients that can lead to lack of treatment adherence. "Our goal is to make sure that every patient who has been prescribed a Merck medicine has access to that medicine," said Richard T. Clark, chairman, president and CEO of Merck. "Merck has been providing free medicines to Medicare Part D beneficiaries through our Patient Assistance Programs for many years. With this new proposal we will go the extra step and offer direct savings to Medicare Part D beneficiaries in the coverage gap regardless of their income." Merck Expands Patient Assistance Programs The Merck Patient Assistance Program remains unchanged; it can provide free medicines to certain Medicare beneficiaries who have trouble affording their medicines. In March, the company increased the number of people who may benefit from the Merck Patient Assistance Program by raising the amount of income potential patients can earn and still qualify to receive Merck medicines for free. Patients in the United States now may be eligible for the program if their household income is at or below 400 percent of the Federal Poverty Level (FPL), which is set by the U.S. government and they are uninsured or otherwise unable to afford their medicines. This means that patients now qualify if they have a household income of $43,320 or less for individuals, $58,280 or less for couples, or $88,200 or less for a family of four, even if the financial situation is temporary due to unemployment or other reasons. Previously, patients were eligible if they were 200 percent or below FPL, which currently is $21,660, $29,140 and $44,100Āš, respectively. The Merck Patient Assistance Program is one of the oldest and most generous assistance programs in the industry. Over the past seven years, Merck has provided more than 1.7 million prescriptions to patients through the Merck Patient Assistance Program, at a value of $1.9 billion. For more information on Merck"s patient assistance programs visit: visit http://www.MerckHelps.com or call (800) PAP-5400. Merck


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):